PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32562081-6	2021	RESULTS: We observed that MSM itself induces apoptosis in EC cell lines, and pre-treatment with MSM for 24 h increases the sensitivity of EC cells to DOX-induced apoptosis and DNA damage and that effect might be regulated by p42/44 (Erk1/2) MAPK and Akt (protein kinase B).	Doxorubicin	150-153	protein tyrosine kinase 2 beta	Homo sapiens	255-271	
32038792-5	2008	Furthermore, the treatment of cells with doxorubicin, DNA-damage inducing agent, leads to PKB phosphorylation on Ser473 in control MEF cells while there is no response in DNA-PK knockout MEF cells.	Doxorubicin	41-52	protein tyrosine kinase 2 beta	Homo sapiens	90-93	
34298726-9	2021	Inhibition studies indicated that FAK is not involved in doxorubicin efflux and chemoresistance, whereas PYK2 inhibition abrogated both VLA-4-induced doxorubicin efflux and chemoresistance.	Doxorubicin	150-161	protein tyrosine kinase 2 beta	Homo sapiens	105-109	
30020827-4	2018	In TRPM2-depleted cells, phosphorylation and expression of Pyk2 and cAMP-responsive element-binding protein (CREB), a downstream target, were significantly reduced after application of the chemotherapeutic agent doxorubicin.	Doxorubicin	212-223	protein tyrosine kinase 2 beta	Homo sapiens	59-63	
31043590-7	2019	Finally, our findings showed that Matrigel/beta1 interaction enhanced doxorubicin efflux and chemoresistance by activating the FAK-related proline-rich tyrosine kinase 2 (PYK2) as both PYK2 inhibitor and siRNA diminished the effect of Matrigel.	Doxorubicin	70-81	protein tyrosine kinase 2 beta	Homo sapiens	139-169	
31043590-7	2019	Finally, our findings showed that Matrigel/beta1 interaction enhanced doxorubicin efflux and chemoresistance by activating the FAK-related proline-rich tyrosine kinase 2 (PYK2) as both PYK2 inhibitor and siRNA diminished the effect of Matrigel.	Doxorubicin	70-81	protein tyrosine kinase 2 beta	Homo sapiens	171-175	
30351976-8	2018	Meanwhile, DOX induced activation of phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt/PKB) and mammalian target of rapamycin (mTOR) pathways that cross talked with AMPK.	Doxorubicin	11-14	protein tyrosine kinase 2 beta	Homo sapiens	74-90	
31707337-12	2020	Combination treatment with DOX and Mag significantly inhibited the activation of phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling, and promoted p38 mitogen-activated protein kinase (MAPK) pathway.	Doxorubicin	27-30	protein tyrosine kinase 2 beta	Homo sapiens	111-127	
25796439-0	2015	Selective targeting of FAK-Pyk2 axis by alpha-naphthoflavone abrogates doxorubicin resistance in breast cancer cells.	Doxorubicin	71-82	protein tyrosine kinase 2 beta	Homo sapiens	27-31	
25796439-4	2015	MCF-7/Dox cells expressed constitutively active forms of the tyrosine kinases: focal adhesion kinase (FAK-Y397) and protein tyrosine kinase 2 beta (Pyk2- Y579/580) compared with parental MCF-7 cells.	Doxorubicin	6-9	protein tyrosine kinase 2 beta	Homo sapiens	148-152